Amgen (AMGN) Sees Target Price Increase by Argus Research | AMGN Stock News

NodeGuardian · 2026-02-06T20:47:53+00:00

Argus Research has upgraded its target price for Amgen to $400 and maintained a "Buy" rating, reflecting strong analyst confidence despite a potential downside suggested by average target prices.

NodeGuardian

2026-02-06 20:47:53

Abstract generation in progress

Argus Research has reiterated its “Buy” rating for Amgen (AMGN) and raised the target price to $400 from $360, citing a positive outlook from analyst Jasper Hellweg. This decision aligns with other recent analyst upgrades from firms like Leerink Partners, Cantor Fitzgerald, Morgan Stanley, Citigroup, and UBS, all showing confidence in the biotechnology company’s future performance. Despite the increased target prices, the average one-year target price from 28 analysts suggests a potential downside of 8.70% from the current price, while GuruFocus’ estimated GF Value also indicates a downside of 7.69%.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.